A Bubble Fit To Burst? China Genome Testing Firms Soar To New Heights
A company set up five years ago is now worth billions and new funding keeps pouring into the white hot genome testing area in China, despite some observers warning that valuations are unjustified and the bubble is fit to burst.
You may also be interested in...
It was a robust month for medtech M&A deal making with 17 deals in May, making it the busiest month of the year to date. The total number of acquisitions beat the number recorded in May last year and picked up slightly from the 14 deals inked in the previous month.
As the end of the year approaches, medtech venture financing activity looks to have picked up in November to be on par with the previous year's level – but not enough to bridge the gap in annual performances.
As the traditional lines between therapeutics and diagnostics become increasingly blurred, genomic testing is growing apace in China, boosted by the country’s national push into precision medicine. Deals and alliances are coming thick and fast as companies jostle for a slice of the growing pie.